fosun internationlal limited€¦ · horizontal collaboration products combination creating...

0

18 FOSUN INTERNATIONLAL LIMITED SHAREHOLDERS MEETING

1

18

Financial Review & Refined Management

复星国际股东大会

FO

SU

N IN

TER

NA

TIO

NA

L L

IMIT

ED

SH

AR

EH

OR

LD

ER

S M

EET

ING

2

18

2019 Annual Performance Highlights

Leverage

53.5%Total Debt/Total Capital5

Return on Equity(ROE)6

12.8%

Total Revenue1

143Billion/RMB

11.1Billion/RMB

Net Profit Attributable to

Shareholders of the Parent

Company3

14.8Billion/RMB

2018: 12.8%; (2014-2019Average: 13.3%)

0.40

Annual Dividend (Including

Interim Dividend)4

Per Share/HKD

Industrial Operating Profit2

Note: 1. Year-on-year growth of 31%; The top five industry companies in 2019 accounted for 81% of revenue; 55% come from mainland China and 45% from overseas countries/regions; Excluding the influence of major mergers and

acquisitions such as La Positiva, Baihe Jiayuan and Tom Tailor, when the share of Yuyuan restructuring was completed in the second half of 2018 and incorporated into the group statement, the revenue in 2019 increased by 14% compared

with the same period last year. 2. With a year-on-year growth of 21%, the industrial operating profit in 2012 was 9.2 billion. The industrial operating profit includes the profit contribution of the affiliated industrial operating companies of the

group and the joint operating enterprises using the equity method；3. The net profit of parent company increased by 10% year on year, the compound growth rate of the past eight years was 23%, and the happiness increased by 24%

significantly.； 4. In 2019, the annual dividend rate is 20.3%, and the compound growth rate of dividend per share from 2015 to 2013 is 24% ；5. 2019 average debt interest rate 5.06% total debt = short and long-term interest-bearing bank loans

and other borrowings，Total capital = total shareholders' equity + total liabilities 6. By the end of 2019, book net assets per share were HDK $16.0/share, and adjusted net assets per share were HKD $24.0/share.

Financial Review1


Financial Review

3

18

Health Happiness Wealth

65%

24%

11%

Pharmaceutical manufacturing and R&D Medical and Health Service

Medical Equipment and Diagnoses

73%

27%

Brand Consumption Tourism Culture

54%

24%

22%

Household Finance Corporate Finance Investment

20192018

29.133.1

20192018

44.9

67.6

20192018

36.143.4

Income（RMB billion）

2019 Revenue: 33.1 Billion RMB

Year-on-Year Growth +14%2019 Revenue: 67.6 Billion RMB

Year-on-Year Growth +50%2019 Revenue: 43.4 Billion RMB

Year-on-Year Growth +20%

Financial Review1

Formed Three Business Income Systems Centring on Family Customers:


Financial Review

4

18 Earnings per Share Book Value per ShareProfits Attributable to the

Shareholders of the Parent Company

1

Double-digit CAGR growth in Profit, EPS and Book Value over the past 8 years

Financial ReviewFinancial Review


5

18• Stable ROE and continuous improvement of the business operations.

• Further improved dividend payout and continue to create returns for shareholders.

• Steady improved dividend payout tatio since 2015，reaching 20.3% in 2019.

• Dividends per share have grown at a compound rate of 24% over the past four years .

• From 2015 to 2019, the total dividends reached 12.85 Billion HKD .

Annual ROE (%)

15.4

12.8

12.2

13.6

12.812.8

10

11

12

13

14

15

16

2014 2015 2016 2017 2018 2019

Annual Dividend Rate（%）

12.9

15.1

19.8 20.0 20.3

10

12

14

16

18

20

22

2015 2016 2017 2018 2019

1

Efforts to Reward Shareholders Continue to Increase

Financial Review


Financial Review

6

18RMB Bn 2017 2018 2019

Total Debt 150.5186.1

208.3

Net Asset 136.4 160.4 180.9

EBITDA 30.8 32.7 44.1

Stable & Healthy Debt Maturity

57%

28%

10%

5%

Debt Breakdown by Currency

RMB USD

EUR Others

Other Financial RatiosLeverage Ratio1（%）

49%

40%

2014 2015 2016 2017 2018 2019

51%

60%

2014 2015 2016 2017 2018 2019

Within 1 Year More than 1 year

55.9%

53.6%

50.7%

52.4%53.7% 53.5%

48.0%

50.0%

52.0%

54.0%

56.0%

58.0%

2014 2015 2016 2017 2018 2019

Note: 1. Leverage ratio = total debt/ total capital; Total debt includes short-term and long-term interest-bearing bank and other borrowings; Total capital equals to total equity plus total debt.


Financial Review1

Stable Leverage Ratio & Debt Level

-2019年Average debt ratio5.06%-In October 2019, Fosun successfully issued a €400 million 3.5-year Senior Unsecured Notes, listed in Irish Stock Exchange, final pricing at 4.35%.

-Final order book surpassed €2.3 billion, representing 5.7x oversubscription with asset managers and insurance accounted for 82% of the order book, while commercial banks and private banks took down 18%

7

18

Refined Management

Multiplication Effect Through Refined Management


2

Objectives

ROE >15%Mature Firms

Incubate Enterprises

Turn Around

Financial Investment

IRR ~20%

IRR ~20%

IRR ~20%

8

18


Organization Development & Asset Management Committee

Co- CHO Risk Management

1+2+7 Strategy

Implement Competitor Benchmarking

Strengthen Career Department, Support From Core Enterprise CFO, Evaluation, Management and etc. for performance appraisal of core enterprise managers

Focus on Core Projects

& Key Steps

Core Business & Indices

C2M +Management

Evaluation & Reward

Organization Development

Operation Goal

2

Multiplication Effect Through Refined Management

Refined Management

9

18


Health Happiness Wealth

• Industry leaders in the sector• Contribute sustainable profits and cash flow• High potentials in value growth

• Continue to build superior products in core sectors• Realized or Target ROE (≥15%) and core assets and high profit growth• Excellent team with innovative and industrial integrating abilities

Investment Criteria for Fundamental Assets:

Investment Criteria for High-Growth Assets:

Investment Criteria for Innovative-Driven Assets:

• Focus on long-term potential and competitive Investments and innovation-driven sector• Invest in talents and capture frontier innovation opportunities• High Ecosystem Synergy among Health, Happiness and Wealth

2

Goals by Pyramid Asset Structure

Refined Management

10

18


Investment Management

Refined Management3

Strategic investment adhere to C2M strategy

Promote the merger and acquisition of head enterprises of C2M racetrack

Wait chance to complete the reinforcement of the core invested enterprises

All subsidiaries focus on the merger and acquisition of their racetrack

Strategic Investment

Fund-like financial investment

Around the C2M strategy, find the right investment target, and

achieve the high growth expectation of core financial data, large

space for value promotion, and effective internal coordination

Financial Investment

Reduce investment level in wartime

Camp sinking, ensure all investors are included

Sticking to strategy, ensuring benefit in special period

Wartime Mechanism Support

Appoint CIO, set up CIO office, make use of

head investment ability to build investment

team and sort out investment mechanism

CIO System Assurance

11

18


Refined Management

Standards and Measures of Various

asset Investment and Exists

Holding Type -Mature Type

Holding Type -Turn Around

Equity Asset in the Primary Market

Asset in the Secondary Market

Fixed-income

• Sell the assets which the profit margin tends to be stable , the growth is limited, and a lack of strategic coordination

• Take stop loss as the main purpose to avoid continuous cash payment in the future

• Normal operation of the project, small space for subsequent valuation improvement, waiting for the opportunity to exit

• Normal project operation, weak business growth, and lack of market refinancing capacity in the follow-up, waiting for the opportunity to exit

• The business situation is general, and the repurchase is expected or triggered. Based on the business situation of the company, the repurchase is recommended

• Long term low efficiency or loss project, strive to quit

• Implement classified management according to investment cost, project profit and loss and strategic purpose

• Implement hierarchical management according to the categories of position holder• At present, it is mainly to choose the opportunity to increase the holding, lay out at a low

level, and carefully select the regions, industries and specific targets, so as to reduce the risk of subsequent volatility

• Forward looking identification, for the subject matter with continuous upward credit risk, reduce the holding in time

• Check the debtor's cash flow, determine the liquidity pressure point, and define the window period of reduction

• Judge the reorganization value and liquidation value of the debtor, and determine the reasonable reduction price

3

Exit Management

12

18复星国际股东大会

FO

SU

N IN

TER

NA

TIO

NA

L L

IMIT

ED

SH

AR

EH

OR

LD

ER

S M

EET

ING

Strategic positioning and top-level design

Covid-19 impact and response measures

Organization evolution and wartime mechanism

Looking beyond the future with the lessons of history

1

2

3

4

13

18

Strategic positioning and top-level design1

To build an innovation-driven consumer group

Be a leading industrial operator in respective

segments

Organic expansion through value investment

with industry insight

Actively tapping capital markets

In-depth business operations

Connect China momentum with

global resources

Connect global momentum with

china resources

Globalization 2.0

Efficiently connecting C- and M-end

Help products reaching target consumer

base with precision

One-stop bespoken service and product

provider for global families

C2M model

Serving one billion global family

customers

Technology innovation +creative design

Improve product competitiveness by creating

flagship products

Innovation-driven

14

18

Strategic positioning and top-level design1

Focusing on C2M

Focusing on Innovation

Focusing on family customers

Focusing on strategic investments

Cultivate the regional markets layout

In-depth business operation, enhancing ROE with top-tier high-growth brands and products

Sector reinforcement

Ecological synergy

Leading innovation

Investment focus

RegionalFocus

IndustrialFocus

StrategicFocus

China Mainland

Europe*

United States

Emerging Markets

Other countries

55%

7%

6%

6%26%

Our strategic priority ——“FOCUS”

FOCUS

Current revenue breakdown

*Note: excluding emerging economies i.e. Turkey, Czech Republic, Hungary, Russia and etc.

15

18

1

C2M

Strategy

Organization Fight

C2M Ecosystem

To build our global C2M ecosystem by optimizing C2M in business sectors vertically, achieving multiplier effect by C2M integration across sectors


Families

Flexible supply chain

Makers

Smart marketing

C2M vertical ecosystem

multiplier effect

Digitalization

2Link

16

18

1

Horizontal collaborationProducts Combination Creating crossover products

C2M to be implemented across all segments

—>One unified C2M ecosystem

FC2M

Internal ecological BDExternal traffic and membership BDIntegrated MarketingCross-selling

Supply chain integrationGlobal marketing

1+N C2M:C2M is implemented across all business segments in order to eventually build up one unified C2M ecosystem


C2Mization forall business segments

Customer

Maker

2Link

Membership operations

/Smart Services

Smart marketing/ Global Marketing

Smart manufacturing

Flexible supply chain

Innovative R&D /Agile development /

product BD

Happiness

Wealth

Healt

hca

re

Serv

ice C2M

Companies

Vertical and horizontal C2M integration

Vertical integration

C2M vertical ecosystem

17


FO

SU

N IN

TER

NA

TIO

NA

L L

IMIT

ED

SH

AR

EH

OR

LD

ER

S M

EET

ING





1

2

3

4

18

18

Covid-19 impact and response measures2

Health

Pharmaceutical sector:• Since March, the domestic pharmaceutical sector

quickly recovered after the epidemic was controlled• The R&D timeline of key products in the

pharmaceutical sector remains unchanged• Gland Pharma has restored to full production after the

disruption in March. It is expected to maintain rapid growth throughout the year thanks to the strong demand due to the covid-19 situation

Medical device and diagnosis sector:• Fosun Long March’s Covid-19 nucleic acid testing kit

has been certified by NMPA, CE and FDA.• Negative pressure ambulance, mobile CT, ventilator

and other medical equipment sales have grown rapidly, actively expanding production capacity, and quickly delivered to the customers

Healthcare sector :• The number of routine outpatients and inpatients

decreased in February and has recovered rapidly since March

• Flagship hospital Foshan Chancheng outpatient volume has returned to the level of same period last year

Vaccine:• Fosun Pharma is licensed by BioNTech to exclusively

develop and commercialize the new Covid-19 vaccine products based on its mRNA technology in China

Covid-19 overall impact

Happiness

Yu Yuan:• First quarter gold and jewelry business revenue

reached 5.4 billion yuan, growing at 1.1% yoy• In the first quarter, the jewelry franchise business

achieved rapid growth against the headwind (+11%). The wholesale order before the Spring Festival in January was 4.4 billion yuan, increasing by 32% yoy. The number of gold jewelry stores reached 2818, increased by 59 in the first quarter, all of which were better than the industry average performance

• During the Covid-19 period, we vigorously developed online business: Laomiao Tmall Store achieved a 213% sales growth in the first quarter

• The operating rate of Yuyuan Phase I merchants recovered from 80% to 95%

Foliday:• ClubMed All five domestic resorts have reopened from early

February to the end of May. The four resorts that have opened in China have seen a significant recovery in consumption. During May 1st holiday, Anji and Yanqing resorts were sold out, and the average occupancy rate of Guilin Resorts exceeded 50%

Oversea resorts closed in late March started to reopen in late May

• Atlantis Though some facilities were closed since January 23,

all were reopened since mid-March The average occupancy rate reached 84% during the

May holiday

Wealth

Insurance:• Portugal Insurance: Health insurance does not cover the cost of Covid-19

treatment, only the cost of testing The existing health insurance contract premium

increased on year-on-year basis• Peak Re: Most life insurance’s reinsurances exclude epidemics Life insurance business actively explores the market's

growing demand for infectious disease reinsurance• Fosun Insurance: Affected by the epidemic, the actual premium

achieved was significantly reduced Actively develop online business, exploring live

streaming + WeChat marketing

Finance:• Fosun Hengli’s investment banking and insurance

brokerage business are affected by the lock down due to covid-19; however the fixed income and securities brokerage business grew rapidly.

Investment:• Group funds are only for major strategic transactions • Core subsidiaries will only invest in industry-

reinforcement projects• Insurance funds mainly invest in stable and safe asset

allocations • Financial investment fund allocated investment in

market hotspots and high-quality track layout

19

18

2

R&D Acceleration

GMP Certification:• Henlius' Trastuzumab (HLX02) production line

has obtained EU GMP certification in April• HLX02 also received positive opinion from EMA

CHMP in MayHanlikang accelerates commercialization:• The 2000L production of Henlius Hanlikang was

approved in April. Two new indicationregistrations were accepted.

CAR-T R&D:• Fosun Kate CD19 CAR-T was included in the

priority review process for listing and registrationin March

• Fosun Kate and Henlius reached strategiccooperation on solid tumor CAR-T / biCAR-Tproduct development in April

Importing new medicine:• Fosun Pharma's first small-molecule innovative

drug avatrobopa tablets approved for listing inChina in April

Generic drug consistency evaluation :• Wanbang pitavastatin calcium tablets, febuxostat,

and bicalutamide tablets of ZhaohuiPharmaceutical have passed the consistencyevaluation of generic drugs in April and May

Embracing the Covid-19 challenge by R&D, sales and online marketing acceleration

Health Sector


Strengthen global Marketing

Testing kit:• Fosun Long March launched new

coronavirus nucleic acid detection kits andexported to multiple countries

Aiding overseas anti-epidemic effort :• Dispatch and support masks, protective

clothing, nucleic acid detection reagents andother medical protective materials to Italy,the United States, France, Germany, theUnited Kingdom, Portugal, Japan, SouthKorea, India and other countries

Global sales of fashion health masks:• Fosun‘s fashion enterprise, i.e. Lanvin,

Wolford, Tom Tailor, St. John and etc.,launched their own fashion masks, takingadvantage of our global C2M productcustomization capabilities and flexiblesupply chain advantages to meet theprotection and fashion needs of our globalhousehold constomers

Improve digital marketing

515 Family Day to promote digitalization andfamily/health-orientated business model

Fosun Health++:• Launched the family-centered online medical

and health platform product "Fosun Health+", upgraded the services of nearly 30offline physical hospitals under Fosun online,and provided online health service includingmedical consultations and live streams fromfamous doctors

Fosun Health Management Plan (FHMO):• Provide online and offline health

management services to help users gradually complete the transit to preventing health management model

20

18Pharmaceutical Sector

Vaccine development :

• Fosun Pharma is licensed by BioNTech to exclusively develop and commercialize covid-19 vaccine based on its mRNA technology in China

• The phase 1/2 clinical trials of the vaccine have already begun in Germany, Fosun Pharma and BioNtech will also conduct clinical trials of the Covid-19 vaccine in China after obtaining regulatory approval

Covid-19 antibody drugs :

• Henlius reached a project cooperation agreement with Sanyou Biology and ZhijiangBiology. The three parties will cooperate to develop fully humanized antibody drugs against the new COVID-19.

2

Fighting the Covid-19 through production ramp-up, R&D acceleration and global collaboration

Health Sector


Medical Device and diagnosis sector

Negative pressure vehicles, ventilator, mobile CT :• An emergent working group was urgently

established to respond to clinical needs• Quickly adjusting the production capacity to

meet the needs of ambulances, ventilators and mobile CT during the outbreak

Testing kit:• Fosun Long March has launched a new

coronavirus nucleic acid detection kit to further meet the needs of epidemic prevention and control, and has obtained certifications from China's NMPA, EU CE and US FDA

• Fosun Health +, Youyibang, Baby Tree, Dr. Xiaoxing, Lily Jiayuan and other platforms united Dean Diagnostics and Bauer Medical Laboratory, as well as many medical institutions under Fosun Medical to provide testing and service for people in over 20 cities, including Beijing and Shanghai

Healthcare Sector

Supporting Covid-19 relieving effort:• Wuhan Jihe Hospital is listed as "Infectious

Disease Ward in Caidian District of Wuhan City" as a designated hospital for the centralized treatment of fever patients in Caidian District of Wuhan City

• The member hospitals of Fosun Pharma set up an expert team to go to the anti-covid-19 front line. 515 patients were cured and discharged, with 0 mortality rate and 0 infection rate among medical staff

Promoting hospital’s online capability:• Online operation capabilities such as online

consultation, health management, and smart hospital services have been improved

21

18

2

Partnered with

51,268registered

doctors

1 milregistered

users

6000-7000Daily consultations

Live Streaming

>100

Fosun’s doctors provided

>2500free clinic service in 3 days

上海市医师协会

上海市中医药学会上海市医学会Hundreds of influential online live streaming lectures

KOL

Tens of thousand of doctors provided free online diagnosis

Nucleic Acid Detection Network in 20+ City

Approx. 30Fosun’s hospitals went

through digitalization

515 Fosun Family Day: Fosun Health+ & FMHO one-stop online diagnosis and treatment, guarding every family member

Health Sector


22

18

2

Sample collection

Nucleic acid extraction

Nucleic acid testing

Result analysis

• 3-Target detection: single-tube detection of ORF1ab and N, E genes

• High sensitivity: 300 copies/mL, leakproof

• Reliable performance: clinical sensitivity 99.53%,

specificity 97.92%, overall coincidence rate 98.48%

• Contamination-proof system: UNG enzyme and dUTP

• Fast and efficient: able to process 96 samples in 2 hours

Vaccine: swiftly launched Covid-19 nucleic acid detection reagents and detection service to help business reopening

Health Sector


https://image.baidu.com/search/detail?ct=503316480&z=&tn=baiduimagedetail&ipn=d&word=%E5%AE%9D%E5%AE%9D%E6%A0%91&step_word=&ie=utf-8&in=&cl=2&lm=-1&st=-1&hd=&latest=&copyright=&cs=2533196868,3404558952&os=1010436751,3432474796&simid=3617931151,524061318&pn=0&rn=1&di=16610&ln=1391&fr=&fmq=1590651764163_R&ic=&s=undefined&se=&sme=&tab=0&width=&height=&face=undefined&is=0,0&istype=2&ist=&jit=&bdtype=0&spn=0&pi=0&gsm=0&objurl=http://pic4.zhimg.com/v2-35fc1ab2e036e18a62ffc0970903776d_1200x500.jpg&rpstart=0&rpnum=0&adpicid=0&force=undefined

https://image.baidu.com/search/detail?ct=503316480&z=&tn=baiduimagedetail&ipn=d&word=%E5%AE%9D%E5%AE%9D%E6%A0%91&step_word=&ie=utf-8&in=&cl=2&lm=-1&st=-1&hd=&latest=&copyright=&cs=2533196868,3404558952&os=1010436751,3432474796&simid=3617931151,524061318&pn=0&rn=1&di=16610&ln=1391&fr=&fmq=1590651764163_R&ic=&s=undefined&se=&sme=&tab=0&width=&height=&face=undefined&is=0,0&istype=2&ist=&jit=&bdtype=0&spn=0&pi=0&gsm=0&objurl=http://pic4.zhimg.com/v2-35fc1ab2e036e18a62ffc0970903776d_1200x500.jpg&rpstart=0&rpnum=0&adpicid=0&force=undefined

https://image.baidu.com/search/detail?ct=503316480&z=&tn=baiduimagedetail&ipn=d&word=%E5%B0%8F%E6%98%9F%E5%8C%BB%E7%94%9F&step_word=&ie=utf-8&in=&cl=2&lm=-1&st=-1&hd=&latest=&copyright=&cs=3188639381,1081704059&os=4198529605,1849333262&simid=0,0&pn=0&rn=1&di=32670&ln=377&fr=&fmq=1590651806375_R&ic=&s=undefined&se=&sme=&tab=0&width=&height=&face=undefined&is=0,0&istype=2&ist=&jit=&bdtype=0&spn=0&pi=0&gsm=0&objurl=http://pic.qqtn.com/up/2018-11/15432012016221769.jpg&rpstart=0&rpnum=0&adpicid=0&force=undefined

https://image.baidu.com/search/detail?ct=503316480&z=&tn=baiduimagedetail&ipn=d&word=%E5%B0%8F%E6%98%9F%E5%8C%BB%E7%94%9F&step_word=&ie=utf-8&in=&cl=2&lm=-1&st=-1&hd=&latest=&copyright=&cs=3188639381,1081704059&os=4198529605,1849333262&simid=0,0&pn=0&rn=1&di=32670&ln=377&fr=&fmq=1590651806375_R&ic=&s=undefined&se=&sme=&tab=0&width=&height=&face=undefined&is=0,0&istype=2&ist=&jit=&bdtype=0&spn=0&pi=0&gsm=0&objurl=http://pic.qqtn.com/up/2018-11/15432012016221769.jpg&rpstart=0&rpnum=0&adpicid=0&force=undefined

23

18

2

Offline features creation

Digital innovation

Active wartime response

Expansion through

consolidation

Product innovation and

upgrade

Happiness Sector


24

18

2

O

n

l

i

n

e

I

n

n

o

v

a

t

i

o

n

Accelerating the digitalization of happiness business with new business models such as live streaming and collaboration with 3rd party platforms

Live streaming

62.4 million

Total sales19.32 million

Online views34.65 million

Atlantis flagship product sales12, 5000 Tong Han Chuntang Dragon Ball Mask Sale

Online Expansion

Old Temple Tmall ShopFirst quarter sales increased

by 213%

515 Total GMV surpasses 100 mil

700k+ viewer, 25k+buyer, 282k follower,

single flagship product 64.42 mil+ sales

Foliday mitigates the impact through digital marketing

17 influencers 28 multi-platform stream15.76 mil+ views, 1.32 mil+ content

interactions, 970k+ sales

Live streaming by 21 shops

13665 viewers, 320k+ sales

Fosun 515 +

"Flying Pig Super

Brand Day" two

main venues with

dual guided flow

LANVIN settled in Siku, Asia's largest online and offline boutique lifestyle platform, and set up a flagship store on Siku APP platform

Feb 10

Feb 26

May 18

Open up #LANVIN online show#This season LANVIN's autumn and winter show joins hands with iQiyi to create a VR immersive experience

The LANVIN 2020 baby elephant Babar capsule series was first launched on Tmall. Previously, it has achieved good results in the online live test of Xiaohongshu.

Flagship products were sold out within

seconds

Happiness Sector


25

18

2

BFC creates a one-stop landmark with trendy vibes

Sales turnover and client flow grows rapidly since March reopening

As of May, sales turnover and client flow have recovered over 90% to normal. BFC also launched tenant promotions in March to speed up recovery

The weekend market activities will also restart in May and the Bund Maple Trail Night will be launched in June.

Yuyuan night market activity was officially launched

From May 22 to June 18, the 55 Shopping Festival, “Guochaoold famous brand“ and Garden Party all had grand opening in Yuyuan

At the same time, Yuyuan night market activity in 2020, which integrates lighting, performing arts and night market, was officially launched

Further improving family customers’ experience through offline features

Bold artistic design across Yangtze River Delta region

CLUB MED Resort Features

Joyview Yanqing ResortYun Shang Winery

Guilin ResortGuangxi cuisine

515 Sales are dazzling

ClubMed generated sales of 5.35 million during 515, Taobao store GMV increased by

3700% from last month

Sanya Atlantis 515 & 618 original sales target is10 million. Actual sales reach 120

million yuan during 515

Empowering business resources, reshaping offline features

Happiness Sector


26

18

核心专利技术K N 9 5 级纳米纤维滤芯

2

Further enhancing competitiveness and innovation by focusing on Fosun C2M ecosystem

Replace the production with the best domestic suppliers in order to smoothly overcome the stagnation of the European supply chain during the pandemic

Fosun Fashion Technology protective masks design samples in 3 days, ship in 5 days, and reverse orders in 3 days

Replace with domestic supplier

ODMCustommadeservice

Flexible and fast

In the production cycle of fashion masks, we ensure a one-stop custom made service tailored to the whole process

supply chain management：Flexible deployment

Selected high-quality fabrics, fit the facial design,

Washable, reusable, optional filter

Skin-friendly

Stable demand

Environmental-friendly

Sufficient supply for the peak demand in May and June

Fosun brand: creating a fashionable life

Diverse fashion appearance options, flexible to match different styles and occasions

Fashion

98.7% filter rate

Nano filter has applied for national patent

≥98.7%

12 hours

Patent

Nano filter cartridge can last 12 hours

Anti-allergic skin-friendly material created by Ergonomic design

Skin-friendly

The filter can withstand alcohol and boiling water

Durability

Cloth masks for sustainable useRecycle

Happiness Sector


Empowered by technology: safe and healthy

I

n

n

o

v

a

t

i

o

n

27

18

2

In March 2020, Fosun Cosmetics Industry Group announced the formal acquisition of skin care products company WEI Beauty, including its three modern Chinese skincare brands WEI (blue beauty), WEI TO GO (Wei Lai) and WEIEAST (Wei Yisi).

In March 2020, Yuyuan announced that it would invest RMB 210 million to acquire the majority share of French jewellery brand DJULA and become a controlling shareholder of DJULIA with a 55.4% shareholding.

The establishment of a partnership with DJULA provides Yuyuan with an opportunity to exchange and cooperate with European and American fashion jewelry. Fosun's global strategic layout will also help DJULA enhance its strength in the global luxury fashion field, thus helping Yuyuan Jewelry Fashion to enter the global market.

Expansion through value investment by leveraging off the current headwind

E

x

p

a

n

s

i

o

n

Happiness Sector


28

18

2Wealth Sector

Promoting the integration of insurance and healthcare ecosystem, creating an insurance + healthcare management service system with Fosun features

16 provincial level institution licenses 50+ Licensed institutions

Actively develop scenario-based sales starting by taking the work area and medical institutions

Establish a unique high-capacity

team centered around value

growth

Obtained A-rating through

Balanced capital structure,

operating performance and risk

management

Channel development

High-quality development

Ecosystem

integration

Onlineconsultation

Diagnosis

Medicare

Insurance+

Providing users with new online and offline medical and health services with online consultation, exploring new forms of HMO

Providing customers with special products of insurance protection, covering health, chronic disease and serious patients, exploring healthcare + insurance

Synergize with hospital resources

Connecting health management and service resources such as high-quality physical examination and genetic testing


Pharmaceutical

29

18

2

• Portugal Insurance: Health insurance products do not need to bear the cost of Covid-19 treatment, but only the cost of testing; reduced economic activities and raised restrictions reduced insurance claims

• Peak Re: Most of life insurance contract reinsurance excludes epidemic diseases; the total life insurance payment is expected to be $2-4m ；

• ATG: The contracts are mainly labor liability insurance, which are not directly affected in most cases

Direct compensation’s impact is limited

New business sales are affected, but overall underwriting profits remain stable

• Pramerica Fosun: Affected by the epidemic, the actual premiums paid by the BPA were significantly reduced, but due to the better performance of the new single-term premiums paid in January, the overall premium structure was improved；

• Portugal Insurance: Due to reduced economic activity, sales of new life insurance orders declined. The overall premium of non-life insurance rose steadily, but claims decreased, and the overall underwriting profit remained stable

Investment income is affected by fluctuations in the capital market, but overall risk is under control

• The overall asset allocation has undergone structural adjustments in 2019, including a reduction in the proportion of stocks and the removal of high-risk fixed income projects, which has greatly reduced the impact of this crisis

Product upgrades and extend product liability

• Upgrade insurance products, expand product liability, include Covid-19 in coverage

Service upgrade: adding 8 more services and protections under T&S

Portugal Insurance subsidiary La Positiva now coversCovid-19

Covid-19 impactResponse Measures

Wealth Sector


Improve service quality and customer care

• Online symptom consultation, provide online test prescriptions, medical staff family services, etc.

Portugal Insurance launched the online Covid-19 consultation service for all customers.

Enhance customer contact and maintain business stability

• Contact customers by phone to extend the premium grace period, etc.

Fosun Insurance launched a remote dual-record operation guide to support channel business development; promote electronic return visits.

Launch online services to promote business process upgrades

• Remote office, online staff addition / presentation, launch of online platform, system function development

Initiating online training platform, improving mobile business system

30

18

2

Portugal Insurance: The premiums for the stock business of health insurance and non-life insurance have increased on yoy basis (+ 5%, + 2%).

Existing businesses show resilience

Outcomes and opportunities

Peak RE: Non-life reinsurance sees substantial growth (27.1% yoy);Actively exploring the market's growing demand for infectious disease reinsurance

Pramerica Fosun: Exploring live streaming + Wechatmarketing; Shifting to online business management

Discover business growth points under Covid-19

Embracing new opportunities for online business

Life insurance

Non-life Insurance

Existing Insurance premium

+5% +2%

1

2

3

Wealth Sector


31


FO

SU

N IN

TER

NA

TIO

NA

L L

IMIT

ED

SH

AR

EH

OR

LD

ER

S M

EET

ING





1

2

3

4

32

18

Organization Upgrades and Wartime Mechanism3

C2M

Strategy

Organization Fight

Fosun's goal of building global C2M ecology requires strong C2M organizational capacity

C2M组织框架体系

MechanismPeople Plans

Mechanism Link Culture Protection

1+N Ecology C2M Multi-Organization

C2M Organizational Framework

Culture

Culture

Culture

Culture

33

18


Vertical and Horizontal Management

Chairman

Co-chairman

Co-CEO

CXO

Health

Sector

Finance

Sector

Hive

SectorHappiness

Sector

Commodities

and intelligent

manufacture

Internet

Vertical

Platform

Horizontal Management

VerticalManagement

Industry ABC CXO

Function line ABC CXO

Program ABC CXO

34

18

Hierarchical organization:Screw employees

Fosun Ecological Leadership:• Self-positioning: From Physical to Ecological, Founers are

holographic cells rather than screws.

• Benefit Consideration：From Self-interest to Altruism, the

benefit of Fosun is the first priority

• Capability Building：Updating four key factors into five key

factors. Among all, digitalisation is the most important one

Ecological organizations: cellular employees

3

Ecology Management

Organization Upgrades and Wartime Mechanism

35

18

Organization Upgrades andWartime Mechanism3

War Ecology

① Global Anti-epidemic War ② Fashion Mask War

③ Fosun 515 Family Day Ecological War

④Health insurance + HMO War

① Industry and city integration war

④ Fosun Financial Cross-sell War

③ Health sector user drainage war

①Laomiao, AHAVA online war ② Atlantis Marketing War

③ COVID-19 testing kits marketing war

④ NISCO efficiency improvement war

② Global supply chain war

Group War

Industry war

Production line war

……

……

……

36

18

3

Security Mechanism

271Coopetition Mechanism

Maintain a "wartime" state and a sense of crisis at all times

Maintain forecast capability, action, organizational and decision- making skills

Promoting talents and resource connection between headquarters/member enterprises, front desk/middle and back office

Realizing the integrated development between industries、sectors, and gather Fosun's ecological synergy

Evolving the team via ranking, appointment, optimisation and etc

Stimulating enthusiasm and keeping high efficiency under competition and cooperation

Organization Upgrades and Wartime Mechanism

Rotation

Mechanism Wartime

Mechanism

37

18


Culture Protection

`

Focus on customer needs, solve customer pain points, enhance customer experience, and maximize value for customers.

Consumer Priority

Actively understand Fosun'sindustry, resources and employees. Good at digging and integrating internal and external resources to achieve self-closed loop of work.

Must have forward-looking judgment and agile execution. Always being 0.01 seconds faster

Stay humble and learn for life. Fully use of Fosun's resources, quickly learn and put into action

FC2M Ecological Logic 0.01 second faster Never Graduating University

Organization has border but responsibility is borderless.Achieving ultimate goal via cooperation

Competition and Cooperation

Actively embrace changes and maintain the market awareness. Solving customer pain points with innovation and promoting the continuous evolution of products and organizations.

Innovation and evolution

Starting from creating values, self-motivation, pursing to the limit and never giving up.

Entrepreneurship

Anchor the right direction, undergo the test, and do not give up until achieving the gaol

Persist in doing the right things, the hard things, the

things that need time to accumulate

38

18

Product linepartners

IndustryPartners

Global Partners

Cover Groups, Sectors, Lines, Enterprises

Cover sector, lines, enterprises

Mainly covering corporate members


Fosun Partner System Matrix

39


FO

SU

N IN

TER

NA

TIO

NA

L L

IMIT

ED

SH

AR

EH

OR

LD

ER

S M

EET

ING





1

2

3

4

40

18

4Operation Direction

Client 2Link Maker

Strengthening the member system construction, in-depth user operation, members and private community

Strengthening precision and intelligent marketing

Improving team/outlet capacity

Expanding various online and offline channels

Implementing global BD and regional expansion

Improving supply chain efficiency and flexibility

Leaning manufacturing, reducing costs and increasing efficiency,

Continuously optimizing lean manufacturing and supply chain

Expanding product and service categories according to customer needs

Continuous investment on innovation

Industry Recap and Future Expectation

41

18

Industry Recap and Future Expectation4

MissionCreating happier lives for

families worldwideVisionRooted in China and creating a global happiness ecosystem fulfilling the needs of one billion families in health, happiness and wealth

Long-Term Goal

42

18

Thank you！

43

18 2020 Fosun Forum and Fosun Investor Day

Development Strategy Fosun Pharma

44

181

2

3

Table of Contents

Development Outlook

4IN Strategy

Cases

45

18

Payment reform led by social insurance

with commercial insurance developing

Replacement process extended from

low-end generics to low-value medical devices and diagnostic products

Pricing mechanism of innovative drugs

Payer Demand Technology & New Model

Unmet demand: control and cure of

oncology/autoimmune disease, rare diseases and chronic diseases

Diversified and differentiated demands for medical services

Clinical application of cell therapy,

gene therapy and AI

Combination therapy of multiple

technologies

Key TakeawaysLifecycle management of existing business and strengthen innovation capability. To strengthen the leading position

with competitive pipeline, integrated operation and international presence.

2019 2020~2021 2023~20282021~2023

1 + 2 + 2 + 5

Survive Grow Accelerate Succeed

Healthcare Reform Progress: policy trends clear; innovation transformation accelerated; competition globalized; and lagged hospital reform

20 Years of Healthcare Reform: Adapting

46

18

Key Focus – Competitive pipeline, integrated operation and prudent internationalization.

Positioning and Vision

2015 20302020

1. Leading in R&D investment

domestically with global BD &

investment capabilities

2. Establishing marketing capabilities in

major markets

3. First phase of digital transformation,

constructing healthcare C2M

ecosystem completed

1. Global R&D capabilities

2. Global BD and investment capabilities

3. Initial global business presence

4. Full-function could system and CRM

system

5. Multinational innovative healthcare

group

1. Internationally competitive for

fundamental R&D

2. Healthcare service becomes the

world-class operation and investment

group

3. Fully intellegentized and the first mover

for cutting edge technologies

4. Global leading position in

manufacturing industry

Nationally Leading

Globally Competitive

World Class

47

181

2

3

Table of Contents

Development Outlook

4IN Strategy

Cases

48

18

Fosun Pharma 4IN Strategy

INnovation

创新

INternationalization

国际化

INtelligentization

智能化

INtegration

整合

• Optimize innovative R&D top level design

• Focus on key areas, develop competitive

technology platforms

• Improve capital operation and

management efficiency

• Enhance global R&D strategic

collaboration

• Integrate global resources, consolidate the

key position in China’s market

• Develop pipelines with global potentials

• Optimize the product portfolio with regards

to needs in specific regions, and build

international market and sales team

• Plan global manufacturing plant, and

optimize global supply chain system

• Speed up the implementation of operational

intelligentization strategy

• Build strong information security system and

compliance standards

• Integrate internal and external internet

healthcare, and build smart hospitals

• Exploit deep in digital innovation

• Improve BUs and sub-platforms’

strategic integration capability

• Optimize project approval and

portfolio management capability

• Plan manufacturing efficiency and

production type as a whole

• Upgrade capital efficiency, spin off

rationally and add in company value

49

18

Innovation: General Principles

01

02

03

04

INnovation Build superior and clinical value-driven product portfolio

Innovative R&D top-level

planning - upgrade

scientific standards,

establish and optimize

the product portfolio

management system.

• Project management and portfolio management system

• Effectiveness, competitive advantage, and talents

• Internal and external SAB to enable project evaluation and decision-making.

Focus on key areas,

build over 5 globally

competitive premium

technology platforms.

• Management separation for innovative and generic pipelines with patent enhancement.

• Strengthen the leading position of biopharmaceuticals within PCG areas

• Clinical-driven product development

Clear innovation

strategies for effective

capital investment and

management.

Strengthen global R&D

partnership, enhance

strategic alliance

management. • Unmet demands oriented

with multiple accesses to innovative technology

• Reasonable R&D expenditure (ratio) and optimized R&D expense allocation to maximize the value of capital

Top-level Planning

Areas of Focus

Optimize capital allocation

Strategic collaboration

• Business development functions at headquarter and subsidiaries

• Strengthen in-licensing teams and capabilities while building out-licensing capabilities for innovative products

• Efficient alliance management.

50

18

Diversified models to seize innovation opportunities in key areas and cutting-edged technologies

• Overall innovation expenditure to be under 15%

• Introduction of high-value projects through global resources

• Establishment of both external and internal scientific committees, empowering the evaluation system

Pro

jec

t ty

pe

sP

ort

folio

st

rate

gie

s

Fundamental research/ early stage

Our own R&D projectsTranslation/ early-to-mid stage

Internal innovative unitsMember enterprises

BiologicsCell therapyGene therapy

Small molecule innovative drugs

Small molecule generics&DDS

Products with clear efficacy/ mature platform enterprises

Focus on products/ platforms to fill gaps

Global top-notched biotech start-ups

Focus on revolutionized technologies

Universities & Institutions/ Scientific teams

Key curative/ breakthrough technologies

In-house R&D

Commercialization/late stage

External

Innovation

Pipeline

expansion

Self-built platforms

Partnerships

Internal incubation

Co-development

VC/PE

External funds

BD

JV

M&A

51

18

Internationalization: Key markets analysis

欧洲 EU

• The 2nd largest regional market• High barriers for market entry• Higher generics price and limited drug pricing freedom than

those in USA, the highest generics penetration rate in the world

中国 CHNThe 1st key

market• High market potential and high

growth rate• Genetics-to-innovative drug

transition• Speed up import substitutions • Focus on domestic market,

providing a strong backup

• High growth rate• Drug needs and values to be

exploited • Already initiated implementation

印度IND

• Mature market and sales capabilities • High growth rate • Drug needs and values to be exploited

非洲 AF(premium

market)• The world-largest singular market, which has a high growth rate

• Dichotomy between generics and innovative drugs

• Uncertainty of China-US relationship

美国 USThe 2nd key market

Future oversea

operation HQ

Other emerging markets (Southeast Asia/ South America)• High sensitivity to trade and exchange rate, reduced growth rate• Specific Southeast Asia drug market needs to be exploited • Certain market maturity in South America, Russia, and mid-Europe

51

52

18

52

Focus on CHN, US, AF, IND and EU, and build comprehensive international capabilities

• CHN: Good quality and affordable

• IND: Cost advantage

• US & EU: collaboration for innovative technology and products with international potential

• Regulatory, registration and clinical management

International R&D International ManufacturingInternational Sales & Marketing Network

Headquarter Support

• AF: Enhance leading position

• US: Build sales platform for generics and innovative products

• IND: Improve local sales & marketing

• Expansion to other overseas market with partners for distribution or joint ventures

• Global manufacturing sites for API, formulation and medical devices

• Domestic + overseas supply chain system with back-up plans to ensure efficient and stable operation

• Manufacturing systems meeting the requirements of development markets

• Strengthen post-investment integration and management capabilities

• Improve international operation and middle-and-back-office support

• Talent rotation mechanism

Fosun Pharma’s international presence and expertise allow in-licensing of overseas products and technology platforms for local production and commercialization, strengthening domestic leading position while improving international competitiveness.

Global for China

53

18

INtegrationEnhancing headquarter capabilities to empower coordinated development among each segment in the system

Core capabilities of Headquarter Empowerment Vision

Discovery and

target validation

Market Entrance

Operation management

Investment and M&A

• Scientists• Decision-making• BD • Clinical• Registration• Efficacy

• KOL Network• Market access• Branding• Compliance

• Group standard• Cross auditing• Efficient manufacturing• Business information

system

• Digital support• Supply chain

• 100-day PMI

• Increase R&D Efficiency

• Improve R&D quality

• Branding and marketing

• Standardized operation

• Digitalized management

• Post-investment integration

R&D Integration

Overall planning for

production and

supply chain

Smart and intelligent

factory

Modern hospital

management

54

18

54

INtelligentizationOutlook of intelligentized healthcare industry

Personalized medicine with AI+ Big data Based on individual genetic differences and combined with AI and algorithm, providing better medical insights and help develop personalized medicines

Digitalization and Networked

healthcareDigitalization and network of medicaldevices, informatization of hospitalmanagement, personalization andremoting of healthcare service

IOTRemote acquisition of physiologicalindices of patients, optimization of service delivery, manufacturing andtransportation and medical datacollection

Digitalized supervision complianceIncorporated with analyzable data, achieving new regulatory and quality

standards

Cost cut and profit increaseThroughout life science R&D and healthcare business business industry chain, digital informatization benefiting cost cut

New healthcare business modelBlurring of segments btw life science, healthcare, wholesale, and retail.

55

181

2

3

Development Outlook

4IN Strategy

Cases

Table of Contents

56

18

Case 1：Sales & Markerting integration and Branding Capability of Wanbang Pharma

0

2,000

4,000

6,000

8,000

2010 2011 2012 2013 2014 2015 2016 2017 2018 2019

0

200

400

600

800

2010 2011 2012 2013 2014 2015 2016 2017 2018 2019

Revenue（million RMB）

Net Profit（million RMB）

• Fosun Pharma’s core subsidiary, actively implementing the

development strategy of Fosun Pharma. Revenue and net

profit continued strong growth with sales & marketing

integration and brand development.

• Successfully developed brands such as “You Li Tong” and

“Bang Zhi”. Created and developed the idea of “Four Hypes”

(hyperglycemia, hypertension, hyperuricemia and

hyperlipidemia).

• As Fosun pharma’s direct sales & marketing platform, the team

has around 3000 sales professionals.

• Core products：

‒ Febuxostat Tablets( You Li Tong)

‒ Pitavastatin (Bang Zhi)

‒ Low Molecular Weight Heparin Sodium for Injection（Su

Ke Xin）

‒ Recombinant human EPO for injection（Yi Bao）

‒ In 2019, sales volume of Febuxostat and Pitavastatin

increased around 105% and 113% respectively, and in

2020 they passed Quality Consistency Evaluation (QCE).

57

18

Timeline2022 2027

Vison: A Respectable, Innovation-oriented, Leading

Pharmaceutical Company

VISION&GOALS

1. Systemic pipeline development (including ANDA).

2. Continuous development of Oral antidiabetic drug and insulin .

3. Leading in manufacture technology and quality standard.

4. R&D team with innovation capability.

5. Development of a chronic diseases management platform with key service and support .

6. Smart manufacturing platforms, online management and service capabilities, and advanced group management.

1. World-leading pharmaceutical enterprise with in-house R&D, manufacturing and sales network.

2. Large portfolio of marketed products and pipeline.

3. Comprehensive online business and operation management.

1. R&D capability focusing on first generic and innovative drugs.

2. Global business landscape starting with Europe and US.

3. Competitive advantage for patient services in China with chronic disease management ecosystem.

4. Intelligentization capability

Mid-term Goal（10 years）Globally Competitive

Long-term Goal（15 years）Word Class

Strategy positioning：1. Enlarge product portfolio of “Four Hypes”, with focus on diabetes

2. Fully align with the 4IN strategy of Fosun Pharma, and lead the development of member enterprises.

2020 20242018 2029

Case 1：Development Strategy of Wanbang

Short-term Goal（5 years）Nationally leading with core business in

Diabetes and chronic disease

58

18

Case 2：Fighting COVID-19 through with industry-wide and world-wide Presence

Fosun Pharma contributes in the fight against COVID-19 with our business through each segment

of the industrial chain. Working groups were set up at headquarter and corresponding teams

within each subsidiary to for preventing and control of COVID-19.

Fosun Long-march’s in-house developed novel coronavirus RT-PCR detection kit obtained

marketing approvals from China NMPA、 EU CE and US FDA.

Fosun Chancheng and Wuhan Jihehospitals become the local

designated treatment hospital. Fosun healthcare group gathered 23 experts

from member hospitals to Wuhan.

Henlius enter into agreement with Sanyou biopharma and Zhijiang biopharma for co-

development of the humanized monoclonal

antibody for the treatment of COVID-19

Manufacturing sites of Breas in Sweden and US increased

production capacity for home-use and hospital-use respiratory

devices.

Ambulances were manufactured at Fosun

Beiling 24/7 to support the increasing needs.

Fosun Pharma entered into a License Agreement with BioNTech for an exclusive license to develop and

commercialize the vaccine product targeting COVID 19 developed based on BioNTech’s proprietary mRNA

technology platform in China.

59

18

Product Features

• Target detection：qualitative detection of ORF1ab gene, N gene and E gene. Reduce recheck

and improve detection efficiency.

• High sensitivity : 300 copies/mL, avoid undetected results.

• Full-process internal monitoring: internal control were used to effectively monitor the whole

detection process of extraction reverse transcription and amplification, to avoid false negative

results.

• Anti-contamination system: UNG enzyme and dUTP were used to effectively prevent the

contamination of PCR amplicon, to avoid false positive results.

• Fully automatic extraction: with rapid nucleic acid extractor and extraction reagent, the

nucleic acid can be extracted and purified quickly and safely, and the detection of 96 samples

can be completed in 2 hours.

Case 2：Fosun Pharma Self-designed RT-PCR detection Kit

Global Sales

• Obtained marketing approvals from China NMPA、 EU CE and US FDA.

• Actively supporting overseas orders coming from the international network of Fosun Group.

• Exported to countries including the US, Korea, Portugal, Hungary, Germany and Indonesia for both donation and sale.

60

18

Thanks！

61

18

Fosun International 2020 Shareholders' Meeting

Investor Forum

Most Recent Progress in Innovative Research & development, and international collaboration in development of mRNA Vaccine against COVID-19 at Fosun Pharma

Ai-Min Hui, MD, PhD, Senior Vice President

President of Global R & D

Chief Medical Officer

Fosun Pharma

62

18

Orphan DrugFast TrackNDAIND

Stem Cell Therapy

2019 - Multiple Zero-Breakthroughs in Fosun Pharma R&D

Tumor Vaccine CAR-T

FKC876 Registrational study

completed

ORIN1001；OpicaponeAVA-CIT；FCN647

Tenapanor (2)；PT-141SAF189 (US)

AVA-CLDGlargine insulin

Recombinant human insulin ORINOVE-1001 FN-1501

63

18

Submit IND(7) IND Approval（6） Submit NDA（1）

美国

中国

NDA Approval（1）

FCN-207(URAT1)＊

FCN-159(MEK)

Aspart & 30

FCN-011 (NTRK)＊

FCN-338 (BCL2)＊

RT002(GL)

FCN-338(BCL2)

SAF-189

FCN-647

Orin1001

Tenarpanor (ESRD-HD)

FCN-207(URAT1)

* Special approval procedures**Including new clinical trials, moving phase I to phase II or expansion phase, or trial completion

Start Clinical Trials (8)**

FKC-876＊Orin1001（ethics approval）SAF-189（Phase II）FCN-411（started the expansion）FCN-437（started the expansion）Avatrombopag CIT（MRCT iniciated）Tenarpanor IBS-C（Ethical Approval）Opicapone（Completed Phase I PK study)

Avatrombopag（CLDT）

FCN-338 (BCL2) SAF-189

(US Phase II）

2020.1-2020.5 - Progresses During COVID-19 Pandemic

Utilizing internet/remote work, time difference of epidemic between China and foreign countries, and complementary of China-US resources,

Submitted 7, and granted 6 INDs, new launch, promotion or completion of 8 clinical trials， submitted 1 NDA， and granted 1 NDA approaval

64

18

64

In the field of innovative drugs, in 2019, 7 new drug clinical

trial applications (IND) and 3 new drug marketing

applications (NDA) were submitted in China, and 20 clinical

trials were conducted simultaneously. In the United States,

one IND submitted, and two INDs approved. ORIN1001 Fast

Track Designation and FN1501 orphan drug designation

were granted. Conducted 3 clinical trials in the US and

Australia.

2017-2019 Global R&D Track

1 37 7

3

20

21 1

3

0

5

10

15

20

25

IND NDA Trial IND NDA Trial IND NDA Trial

2017 2018 2019

China USA R & D effectiveness：

Clinical trials of innovative drugs：2017/2018/2019 1/8/23

IND：2017/2018/2019 2/5/8

NDA：2017/2018/2019 0/0/3

2018 First International Clinical Trial – FN1501(USA, Aus.)

2019 First First-in-class clinical trial - ORIN1001

2019 First US FDA Fast Track Designation– ORIN1001

2019 First FDA orphan drug designation - FN1501

Building up system:

2018~：Strengthening Clinical and Regulatory team in China

2018：Clinical and Regulatory team established in US

2018~：China and US communication mechanism established

2019： Scientific Committee, R&D Management Committee,

Clinical and Regulatory Review Committee established

End of 2019：Global R & D Center established

International Conference：

2019： ASCO - FN1501

2019： ESMO – FCN159

2

Fosun Pharma’s achievements in the past three years have laid and foretold the future success of

innovative medicines

65

18

Successful Corporation mRNA Vaccine

Fosun's overall view on the epidemic and strong sense of social responsibility

Fosun Pharma R & D capabilities and rapid response

Advantages of mRNA vaccine

BioNTech's leading technology

Short R & D cycle Dual action mechanisms:

Humoral / cellular immunity Strong efficacy, no adjuvant

required Safe Simple manufacture process Rapid mass production

Joint-development of mRNA Vaccine against COVID-19 with BioNTech

Three days after collaboration, the market value of BioNTech increased by 300%, ~ $ 7 billion to ~ $ 21 billion

Feb Outbreak Forecast

mRNA Vaccine

Diversified mRNA technology Comprehensive R & D

capabilities Strong and safe lipid

nanoparticle delivery More than 250 cases of human

mRNA experience Preliminary clinical efficacy of

tumor vaccine High manufacturing capacity Broad Immunotherapy platform

BioNTech's Leading Technology

Uridine mRNA

(uRNA)

Nucleoside-modified mRNA

(modRNA)Self-amplifying mRNA

(saRNA)

BioNTech

66

18First t-con

with BioNTech

China Phase ISigned

Cooperation Agreement

Submit Projectreport to CDE

Fosun R&D Team completed the clinical registration plan and phase 1-3 clinical trial

design.

Sign NDA

Fosun CDE

BioNTechPEI

Four-party conference

Fosun Pharma BioNTech,

CDE Three-party Conference

Meet with BioNTech CEO

Animal challenge

test

01/29 02/05 02/09 02/14 02/18 02/24 03/13 04/08 05/04

Fosun secured Chinese right first

CDE response in

2h

Sign MOU

GermanyPhase I initiated

Pfizer announced cooperation

with BioNTech

04/2303/16

Cooperation History and Progress

04/22

USA Phase I initiated

Global Pivotal Trial

67

18

From Fosun to Globe

Artesunate

From antimalarial to vaccines against COVID-19, Fosun Pharma demonstrates its commitment to social responsibility.

Artesunate, a typical innovation medicine from China, has been exported to overseas and saved thoughts of lives, seeking for approvals in Europe and US in the future

68

18

Thank you！

69

18

复星国际2020年股东大会投资者论坛

复宏汉霖商业化发展与战略

Henlius Commercialization & Strategy

张文杰

Wenjie ZHANG

03 Jun 2020

70

18

复宏汉霖使命愿景Mission & Vision

使命 Mission 持续创新，卓越运营；以优质生物药，造福全球病患。To improve patients' lives by timely providing them with quality and affordable protein therapeutics through technical innovationand operational excellence.

愿景 Vision 专注提供质高价优的生物药，成为全球最受信赖和景仰的创新生物医药公司。

Be the most trusted and admired biotech company providing innovative and affordable medicines for all patients.

致力于患者可负担的创新

Affordable Innovation

秉质前行 · 布局全球Quality Focus · Global Footprints

生物类似药 + 生物创新药 + 联合治疗Biosimilars + Bio-innovatives + Combo

患者可负担的创新Affordable Innovation

值得信赖的品质Reliable Quality

71

18

公司概况和重要里程碑Company Introduction & Milestone Achievements

years10California

China Taipei

Shanghai

02个产品NDA/MAA受理

Products NDA/MAA filed

14000L商业化产能

Manufacturing capacity for commercial products

01个产品成功上市

Product successfully launched

10+8个临床在研产品/联合疗法

Products/ combos in clinical development

1100+ 全职员工Full-time staff

42% 博士&硕士PhD & Master’s

首个单抗HLX01递交IND申请First NMPA IND filed (HLX01)

2011.12

复宏汉霖成立Shanghai Henlius Biotech Inc. founded

2010.02

国际GMP标准产业化基地建设完成GMP manufacturing facility in operation

2015.12

生产厂房获欧盟QP审查通过MNF facility passed EU QP audits

2016.08

HLX01获NMPA NDA批准HLX01 NMPA NDA approved

2019.02

HLX02 EMA MAA受理HLX02 EMA MAA accepted

2019.06

香港上市 (股票代码2696.HK）IPO on HKEX

2019.09

2019.12 HLX02 EMA MAA现场检查HLX02 EMA MAA inspection

2020.04 HLX02 EMA 徐汇基地GMP正式获批HLX02 EMA Xuhui facility GMP approved

2020.05 HLX02 获EMA CHMP推荐批准HLX02 received EMA CHMP positive opinion

72

18

快速变化的生物药创新环境，机遇与挑战并存Opportunities and Challenges Co-exist in a Rapidly Changing Environment for Bio-innovatives

+48

政策持续鼓励创新The Government Continues Encouraging Innovations

201920182017

-58%-54%-50%

医保降价趋势明显Price-reduction in NRDL Is Significant

本土创新竞争激烈Local Innovation Competition Is Fierce

2019 国谈结果暗示支持本土创新的风向2019 NRDL Outcomes Implied A Trend Favoring Local Innovation

在鼓励创新但同时激烈降价及竞争的复杂环境下，质高价优的生物药产品势必创造‘选择性利好’In a complicated environment encouraging innovations but with fierce price-cut pressure, products with high-quality and appropriate price could be more favoured

首次谈判肿瘤药物Anti-cancer drugs first-time NRDL-listers

续约肿瘤药物Anti-cancer drugs re-negotiators

-27%

2019

• 优先审评审批制度Priority review and approval system

• 上市许可持有人制度 (MAH)MAH system

• 创新药试验数据保护Innovative product study data protection

• …

• 对临床急需的新药予以优先审评审批Give priority to novel therapies that are urgently needed in clinical practice

• 临床试验默示许可制Implied CTA/CTP mechanism

• …

进口肿瘤药物Imported anti-cancer drugs

本土肿瘤药物Local anti-cancer drugs

-51%-36%

2019国谈降价幅度（%）2019 NRDL Price-reduction Range (%)

国谈降价幅度（%）NRDL Price-reduction Range (%)

15

临床三期Ph 3

上市申请NDA filed

3

获批NDA approved

6

本土生物类似药研发管线和上市情况Local Biosimilars Pipeline and Launch Status

英夫利昔单抗

阿达木单抗

曲妥珠单抗

贝伐珠单抗

利妥昔单抗

信息来源：IQVIA Analysis; 2019 McKinsey Biocentury report

73

18

聚焦政策影响、生产能力、产品组合、商业运营，打造中国生物药的领导者地位

生物类似药Biosimilars

• 持续发展生物类似药并进一步巩固龙头地位，发挥先发优势Continue developing biosimilars, further strengthen leading position, and capitalize on first-entrant advantages

• HLX01 (“汉利康”，rituximab)

• HLX02（曲妥珠单抗, trastuzumab）

• HLX03 (阿达木单抗, adalimumab）

• HLX04（贝伐珠单抗, bevacizumab）

• >6 后续生物类似药>6 other biosimilars

生物创新药Bio-Innovatives

• 利用专有的单抗开发平台持续开发生物创新药，增强竞争优势Develop bio-innovatives by leveraging Henlius proprietary mAb platform for competitive advantages

• HLX24 (CD47)

• HLX26 (LAG3)

• HLX53 (TIGIT)

• >15 后续生物创新药（包括双抗）>15 other bio-innovatives (incl. bispecific antibodies)

免疫联合疗法I/O Combos

• 以HLX10（PD-1）为轴心的I/O联合疗法HLX10 (PD-1) as the backbone of I/O combos

• 非小细胞肺癌 NSCLC

• 小细胞肺癌 SCLC

• 肝癌 HCC

• 头颈部鳞癌 SCCHN

• >12 不同癌种/适应症临床试验>12 cancer types/ indications in clinical development

商业化生产Manufacturing for

Commercial Products

• 宜山路商业化生产基地：

14,000LYishan MNF plant: 14,000L

• 松江1、2厂全面投产后支持未来全球商业化需求SJ1/2 plants will support global commercial demands once put in full operation

• 一次性生产技术使用先驱者Single-use tech pioneer

• 符合国际标准的质量管理体系Quality system with international standards

商业运营Commercialization

• 助力并影响可持续的生物类似药政策发展Promote and influence China policy-making for biosimilar industry sustainable growth

• 打造患者为中心共赢生态圈Create a patient-centric, win-win ecosystem

• 通过内部销售和营销团队以及合作伙伴加强商业化能力Strengthen commercialization capabilities through sales and marketing teams, as well as external partnerships

Focusing on Policy-shaping, Manufacturing Capacity, Portfolio Synergy, Commercial Operation, Henlius to Establish a Leading Position in China Biopharm Industry

74

18

汉利康®（HLX01）获批开启中国生物类似药新时代汉利康® (HLX01)’s Approval Started a New Era of China Biosimilars

2019.02 HLX01 (汉利康®）NDA获得NMPA批准HLX01 (汉利康®）NDA approved by NMPA

• 中国首例根据《生物类似药指导原则》获批上市的单抗药物China’s first approved monoclonal antibody based on‘Guiding Principles of Biosimilars’

2019.05 汉利康®开出首张临床处方The first prescription of 汉利康®

• 中国首例商业化推出的生物类似药China’s first commercially launched biosimilar

2019.02 HLX01相似性研究结果发表于 mAbs 期刊Research on HLX01 similarity published on the Journal of mAbs

• 中国首篇公开发表的评估生物类似药相似性的文章China’s first published article evaluating similarity of biosimilars

75

18

秉质前行，HLX02的国际化战略布局开始落地Advancing with High-quality Standard, Implement the Globalization of HLX02

Quality Attributes Methods HLX Originator

FcRn biding SPR 19 v v

FcyR binding SPR 20 v v

Target binding Cell based or ELISA binding assay 21 v v

Anti-proliferation potency Cell based assay 22 v v

C1q binding ELISA 23 v v

CDC potency Cell based CDC assay 24 v v

ADCC potency Cell based ADCC assay 25 v v

Apoptosis Cell based apoptosis assay 26 v v

Others Stress stability 40℃ R-PM-UPLC-MS/CEX/SEC 27 v v

PK in Cynomolgus Monkey 28 v v

Toxicology - Single Dose 29 v v

Toxicology - Multiple Doses 30 v v

Immunogenicity Study in Monkeys 31 v v

Cli

nic

al D

ata

Pac

kag

es

32

Structural Characterization and Biosimilarity Data Package mAbs

Category

Fucn

tio

nal

Ch

arac

teri

zati

on Target and

receptor binding

Bioactivity

Pre

-

Cli

nic

al

Dat

a

Randomized head-to-head comparability studies with biosimilar and

originators (EU/China sourced) products to show similarity in terms of PK/PD,

quality, safety, and efficacy.

Data in preparation

Quality Attributes Methods HLX Originator

R-PM-UPLC-MS 1 v v

NR-PM-UPLC-MS (two enzymes) 2 v v

Intact MS 3 v v

LC and HC MS 4 v v

Disulfide bridging NR-PM-UPLC-MS 5 v v

Free thiols Ellman's assay 6 v v

DSC 7 v v

FTIR 8 v v

CD 9 v v

CEX digested/undigestd 10 v v

CEX fragments identification 11 v v

isoelectric point IEF or cIEF 12 v v

Glycation Boronate affinity 13 v v

Modifications R-PM-UPLC-MS 14 v v

Glycosylation Glycosylation NP-UPLC-FL-MS 15 v vSEC-MALLSSEC-HPLC and SEC-

MALLS16 v v

AUC 17 v v

MW and purity NR/R-CE-SDS 18 v v

Structural Characterization and Biosimilarity Data Package mAbs

Category

Ph

ysic

och

emic

al C

har

acte

riza

tio

n

Primary structure Amino acid sequence

Higher order

structure Secondary and tertiary

structure

General charge

heterogeneity and

modifications

Charge heterogeneity

Size

heterogeneity

LMW, HMW and

monomer

自产品研发之初（Pre-IND）即对标欧盟标准Benchmarked EU standard from pre-IND development

2010 2020.052017 – 2018

• Accord: 泛欧洲，中东北非地区Accord: Pan Europe, & MENA

• Jacobson: 香港，澳门Jacobson: Hong Kong & Macau

• Cipla: 澳大利亚，新西兰，马来西亚，哥伦比亚Cipla: Australia, New Zealand, Malaysia, Columbia

2019.12

与国际知名药企签订海外授权许可Entered overseas licensing agreement with international partners

2015

按照国际标准和建造厂房Built MNF facilities with global standards

• 中国首个开展国际多中心3期临床研究的生物类似药（2017 – 2019）China first biosimilar started global multi-center Phase 3 clinical trials (2017 – 2019)

• 中国首个在欧盟报产的国产单抗生物类似药，同时系首个被欧盟受理的“中国籍”曲妥珠单抗（2019.06）China first domestic mAb biosimilar to file NDA in the EU, as the first ‘Chinese’ trastuzumab (2019.06)

2020.04

HLX02 EMA 徐汇基地GMP正式获批HLX02 EMA Xuhui facility GMP approved

HLX02 EMA MAA现场检查HLX02 EMA MAA inspection

HLX02 获EMA CHMP推荐批准HLX02 received EMA CHMP positive opinion

76

18

复宏汉霖产品管线战略“高效创新”三步走3-Step Strategy for ‘Smart Innovation’ of Henlius’ Pipeline

2020 – 2021

短期目标Short-term Goal

高品质生物类似药作

为持续的重点产品High-quality biosimilars remain as

Henlius core franchise

• 生物类似药研发领域国内领先，保持领头羊地位Maintain the leading position in biosimilar R&D in China

• 达成风险管控和稳定收益Achieve risk-control and stable income

短/ 中期目标Short-/mid-term Goal

2022 – 2024

创新药的快速跟进Fast follower innovation

• 在所选择的瘤种/靶点完成创新药管线的补强和开发Complementary R&D for innovative products in selected cancer types/ targets

• 研发重心由生物类似药渐进至创新生物药R&D focus gradually shifts from biosimilars to bio-innovatives

• 初步建立和外部科研机构的长期合作Establish preliminary long-term collaboration with external academic institutions

2024+

中/ 长期目标Mid-/long-term Goal

创新药的"最"快速跟进Fastest follower innovation

“同类第一"药物创新First (wave)-in-class innovation

• 创新药跟进机制完整建立Fully established follow-up mechanism for innovative products

• 在所选的靶点/ 目标管线，实现POC 12个月内快速进入研发For selected targets/ pipeline, enter R&D process within 12 months post-POC

• 借由外部合作及长期长期建立的科研基础，实现“同类第一”药物的成功开发及POCRealize successful R&D and POC of ‘first-in-class’ products based on long-established collaboration with external academic institutions

• 形成高回报的产品线组合Form a portfolio with high commercial return

77

18

近期汉霖生产方面佳报频传，三项重大里程碑如期达成Recently, Three Major Manufacturing Milestones Achieved as Scheduled

徐汇基地

• 2020.04.14 HLX01 2,000L 获批2020.04.14 HLX01 2,000L approved

• 2020.04.17-20 HLX02 EMA GMP获批2020.04.17-20 HLX02 EMA GMP approved

• 14,000L 产能14,000L manufacturing capacity

• 目前支持汉利康商业化生产Currently supply HLX01

• 2020.04.05启动试生产2020.04.05 Commenced test-run

• 规划产能24,000升Planned capacity of 24,000L

• 为松江基地（二）投产前生产需求作

好准备Prepare to fill in the demand before SJ2 is ready

• 总计划用地面积约200亩Total area ~200 mu

• 2019年6月破土动工2019 Jun started the construction

• 预计2021年完工投入试生产并开展相

关验证工作Expected to complete and test-run in 2021

徐汇基地Xuhui

松江基地（一）

Songjiang 1

松江基地（二）

Songjiang 2

黄玮SVP 生产 (MNF) 及工程 (ENG)(曾就职于Newa, REG, Fluor, Baxter)

许圣昌SVP 技术运营 (TO) 及CMC （曾就职于Pieris, Takeda, AstraZeneca, Alexion)

蒋彩花SVP 质量管理 (Quality)（曾就职于TwiB, Aphena, Boehringer Ingelheim)

78

18

国际标准的生产技术和产品: 高效的产能及高度竞争力的生产成本International Standards in Biomanufacturing: Efficient Production Capacity and Highly Competitive COGS

扩大整体产能，满足未来需求Expand MNF capacity to meet future demands

• 优化生产流程，提升效率，达成适用全球商业化的质量体系，包含EMA GMP、US FDA以及其他国家的检查Optimize production process, improve efficiency, and achieve a quality system suitable for global commercialization, incl. inspections from the EMA GMP, US FDA and other markets

迅猛增长的销量预估需要完善的中长期产能布局及可靠的高质量产品供应作为支持The rapid growth of commercial demands needs to be supported by sufficient mid-/long-term MNF capacity and reliable high-quality supply

加速 high titer 的研发Accelerate the development of high titer tech

• High titer的及时研发及申报来确保商业化生产的及时供应及成本控制The development of high titer will ensure timely supply and cost control of MNF for commercialized products

可能方向Potential direction

高表达细胞株、培养基及新工艺研发High-expression cell line, medium and new tech development

• 连续流生产技术、高密度灌注细胞培养等新技术来进一步确保复宏汉霖在生物药商业化生产上的领先地位Continuous production, high-density perfusion cell culture and other new techs to further ensure Henlius leading position in biologicals

79

18

一支强大的商业化团队已经蓄势待发A Strong Commercial Team is Fully Prepared

张文杰

Wenjie Zhang

总裁

President

商业化核心领导团队特征：1）高度的专业水平；2）优异的职业记录；3）良好的领导能力Characteristics of commercial core leadership team: 1) high professional level; 2) excellent career record; 3) distinct leadership

余诚Kurt Yu

市场和商业运营Marketing & Commercial Operation

曾祖运Wallis Zeng

销售运营Sales Operations

钱晓晓Xiaoxiao Qian

战略规划Strategic Planning

葛珺Jun Ge

精益运营Operation Effectiveness

80

18

未来复宏汉霖商业化战略规划Henlius Commercialization Strategic Planning

• 商业化模式创新与外部合作：Innovation in business model and external collaboration

– 多方协作的共赢策略：与药促会等多方合作伙伴积极配合The win-win strategy of collaboration with multi-stakeholders, such as Sino-PhIRDA

– 共建国内生物类似药生态圈Build a biosimilar ecosystem in China

• HLX02的卓越上市是2020年工作重中之重，也将成为复宏汉霖商业化道路上的引擎、成功基石HLX02 launch excellence is the top priority in 2020, which will also become the power engine and cornerstone of Henlius successful commercialization

• 生产能力强化：Manufacturing capacity enhancement

– 加速产能最优化、最大化的同时，打造“汉霖制造，国际品质”品牌形象While accelerating the optimization and maximization of MNF capacity, establish the trademark of “Henlius-made, international quality”

– 战略规划远期海内外生物药生产基地Strategically plan long-term China and overseas production bases

• 商业运营优化：Commercialization optimization

– 销售（团队管理）Sales (field force management)

– 市场（渗透）Marketing (penetration)

– 准入（价格策略、支付计划等）Market access (pricing strategy, payment plan, etc.）

– 商务（经销商管理）Channel (distributor management)1

• 人才 + 能力 + 文化为基础的组织模型：Talent + Ca11111pability + Culture as the basis of organization

– 最优人才The best talents

– 高效团队Efficient teams

– 合规化理念Compliance-based

• BD：

– 与复星医药优势互补，建立产品开发战略合作Complement with Fosun Pharma strengths in product development

– 积极开拓海内外BD机会，包括产品 license-out 和合资企业等形式Actively explore BD opportunities domestically and globally, incl. license-out and joint ventures

HLX02

81

18

81

谢谢Thank you

82

18

Fast Expansion of Jewelry & Fashion Business

Huang zhenYuyuan Inc, CEO

83

18

YUYUAN | Operation + Investment，to be a Global Leader in Family Consumer Goods

84

18

YUYUAN | Online business upgrade + Offline channel expansion

Live stream with top socialinfluencer ： i.e. 薇娅 Viyashow in 12th Apr, achievedGMV of Rmb 25m with28.6m visitors

Self live stream：build upour own team ， over 450shows this year

Private domain trafficmarketing ： serve ourloyalty customers one byone directly，achieved overRmb 10m sales

Cover all business：Jewelry& Fashion, Restaurants, F&B,Property and etc.

Offline Expansion

Jewelry & Fashion expansion：2,818 stores by 1Qwith net increase of 59

Restaurant chaining：Songhelou Noodle opened 2new stores in Shanghai and Suzhou, and will continue

New property projects ： two new projects inChangsha and Shanghai cities

Online Upgrade

85

18

Recurring Net ProfitRevenue

+39.2 %

+27.1 %

+58.4%

+35.8 %

Unit：Rmb100m Unit: Rmb 100m

Gross Margin

YUYUAN | High growth in revenue and recurring net profit in 1Q

58.2

81.1

103.0

2018 Q1 2019 Q1 2020 Q1

1.7

2.7

3.6

2018 Q1 2019 Q1 2020 Q1

15.3%17.1%

18.5%

2018 Q1 2019 Q1 2020 Q1

+1.74pct

+1.4pct

Jewelry & Fashion：Revenue was Rmb5.4bn（+1.1% YoY）; 32% YoY sales increase in Spring Festival product

order fair for franchisees in January.

Property development：High growth in revenue (+119% YoY）

Work Resumption from COVID-19: Full recovery of business already, demand is recovering

Top-rated Financing：Company credit rating AAA; Rmb 1.9bn 5-year-corporate bond offered in Feb with a low

interest rate at 3.6% ; Rmb 1bn 125-day-SCP in May with a low interest rate at 2.2%

86

18

Revenue The 2020 phased strategic objectives are highly consistent with wartime response measuresThe change of epidemic situation has accelerated the implementation of the strategy to support steady development

49.05

53.3953.96

2018 Q1 2019 Q1 2020 Q1

1.1%

8.8%

CAGR：4.89%

Membership

Globalization

Digital Intellige

nce

InternalBD

145

167

205

2017 2018 2019

CAGR: 18.5%

Unit：RMB 100m

15%

23%

2020 phased strategic tasks

Bestseller Products

Channel

Jewelry | High quality transformation and upgrading of YUYUAN’sjewelry & fashion business

87

18 Construct private-domain marketing networks which maintain good

customer relationship and compensate current sales More than 300 Streaming channels covering up to 200 offline stores,

with over 14,000 users Achieve a cumulative sale of over 15 million RMB

The first few players to introduce live stream with social influencer, and cooperate with top hosts for many times

Establish self live stream networks with professional streaming platform

Cross-Industry empowerment: 450+ live streams by the end of May, and leading sales of over 12 million RMB

Laomiao's sales revenue on T-mall has increased 204% by the end of May, highest growth rate within the category

Synergy between Yayi and T-mall hatched new bestseller product through Live Streaming

Has newly opened multivariate online shopping channels for promoting product sales

“IGI Cloud College”has been launched The“Knowledge Lecture Theatre”Live Stream Channel has attracted

more than 12,000 viewers with over 6,000 comments Launched Cloud-based Retailing Supporting Plans, Live Stream Cloud

Jewelry Forums, and has built a cloud alumni network

Enhanced users’privileges and empowered different industries within the system

Crafted a Laomiao franchise System for members More than 225,000 new users with sales figure of over 740 million RMB

by the end of May

Jewelry | Rapid implemention of digital intelligence and new retail measures

88

18

Jewelry | Quality products help continuous product mix optimization

LaoMiao X Mak Ling Ling Continuous good fortune X Guo Qilin Flowers blooming・Diamond Wedding Series

Join hands with metaphysical head IP to empower the connotation of good fortune

best-seller products once launched Cumulative sales of 53,000 pieces and RMB 37 million

good fortune X Kylinspokesperson of series× special endorsement

Warm up is sought after by enthusiasm, try the fan economy

M&A, integration strategyEmpowering category breakthroughs

Launch more and more popular productsAccurately capture good fortune element symbol

Quality products with high gross margin contributes product mix optimizationUsing K-gold and gem-set as the starting point to promote the breakthrough of OEM model

89

18

Jewelry | Systematically improve the operation of direct stores

Upgrade the image of LaoMiao and YaYi direct stores

Strengthen the positioning of the cultural flagship store at

LaoMiao Jingrong Building

Plan the positioning and image of LaoMiao Light Luxury Store

and Guyun Antique Store

"Store manager training camp“ makes preparations for

operating talents

271 Cooperative-Cooperation mechanism 2.0 started

Continuous inventory optimization

90

18Cooperation beyond business

relationsProvide diverse membership

benefits

Standardize and unifyProduct, Image, Promotion,

TrainingDigital intelligence approach to

reach the franchiseMembership, Data, “New

retail”

Key ClientStrategic Alliance

Overcome difficulties with franchisees

Extend receivables collection period to ease financial pressure

Clear inventory and optimize mix amid gold price fluctuations

Selling products through e-commerce channels

Policy Support

Turn crisis into opportunity, raise the target of the store openingRespond to market impact with

development

Lower the policy threshold to encourage franchisees to expand

their storesSeize regional opportunities of

reversing brandYayi entered the stage of fast expansion in many provinces

Channel Development

Jewelry | Policies deepen cooperation with franchisees

91

18

Completed the acquisition of French

designer jewelry brand DJULA, holding

55.4% equity

Improve the brand matrix layout of the

jewelry & fashsion group in the field of

accessible luxury jewelry loved by young

customers

To promote the designer's inspiration

fusion of Chinese and Western elements

Quickly launch China store opening plan

• Beijing SKP

• Shanghai BFC

TBC…

Jewelry | M&A strategy to build brand matrix

92

18

THANK YOU

93

18

Atlantis Sanya -

Successful Experience

and Future Prospect

Fosun Tourism Group(01992.hk)

Chairman and CEO - Jim Qian

June 2020

94

18

Successful model of domestic tourism destinations

95

18

Why Sanya,Hainan?

Superior natural endowments

• Located at 18 degrees north latitude, Sanya is the only tropical coastal city inChina, with a coastline of 258 kilometers, 19 bays and sandy beaches

Sanya tourism dilemma and opportunities

• Highly homogenized high star hotels• Lack of vacation content and diversified experience• Relatively low cost performance

Sanya is one of the most popular tourism destinations in China

• In 2014, there were 13.5 million tourist visits, generating RMB 27.0 billiontourism revenue. In the following six years, the annual growth rate of touristvisits was 12%, reaching 24.0 million in 2019. Tourism revenue grew at anaverage annual rate of 19%, reaching RMB63.3 billion in 2019

Sanya Atlantis led the revenue growth of Haitang bay by more than 50%

Haitang Bay

41.1%

Sanya Bay

13.3%Yalong Bay

12.8%

205

656

1H 2018 1H 2019

Business Volume of Atlantis Sanya

220%

Domestic leisure vacation development trend

• In 2014, the number of Chinese tourists reached 3.6 billion, and it reached 6billion in 2019, with an annual compounded growth rate of 11%.Tourismrevenue grew from RMB3.03 trillion to RMB5.73 trillion, with an annualcompounded growth rate of 14%

Information Source: “Analysis of 1H 2019 Sanya economic operation” by Sanya Government

96

18

Development History of Atlantis Sanya

2014

Acquired land

and started

construction

2016.11

Pre-sale of Tang

Residential vacation unit

2017.12

RMB7 billion cash inflow from pre-sale of Tang Residence

2018.2.15

Soft Opening

2018.4.28

Official Opening

2018.12.31

Business Volume of

RMB753 million in its

first year operation

2019.12

Business Volume of RMB1,312 million in first full year operation

2020.3

Issued CMBS and

raised RMB7 billion

97

18

Strength of Atlantis Sanya

Located at the only tropical coastal city in China, sanya receives 24 million overnight visitors annually

Located in Haitang bay, which has 30+ five-star hotels, it is within walking distance to Haitang bay international shopping center, one of the largest duty-free shops in the world

Favorable geographical location

Hainan free trade port, the only free trade port with Chinese characteristics

Strategic position of Hainan as an international tourism and consumption center

Beneficial Policy Support

The third Atlantis in the world, the only Atlantis in the Pacific region

Representative product of Hainan tourism upgrade 3.0.With 1,314 guest rooms, one of the largest natural seawater Aquariums in China, 86,000 fish, and Aquaventure Waterpark which can accommodate 13,500 visitors at the same time

Top Global IP and Product Power

Comprehensive tourism destination that provides leisure accommodation and catering, water sports, performing arts, children's play and learning services

Fosun Tourism Group has successively introduced Club Med, Thomas Cook sanya travel agency, Miniversity and Fanxiu into Sanya, Hainan

FOLIDAY Ecosystem

https://www.fosun.com/wp-content/uploads/a13-14.jpg

https://www.fosun.com/wp-content/uploads/a13-14.jpg

98

18

Strong Financial Performance of Atlantis Sanya

1,916 2,167

58.0%68.5%

2018 2019

Commentary

753

1,312

2018 2019

1,112

1,485

2018 2019

Business volume

(RMB in mn)

Breakdown of business volume

(RMB in mn)

ADR and occupancy rate

(RMB)

RevPar by room

(RMB)

74.2%

13.1%

33.5%

430

712

323

600

2018 2019

85.8%

65.6%

Business volume increased by

74.2% to RMB 1,312.1 mn in 2019.

22.6% growth was recorded on YoY

basis during May to Dec 2019.

The adjusted EBITDA of Atlantis

Sanya increased to RMB 564.8 mn

in 2019

5.2 mn visits to Atlantis Sanya in

2019, including 1.11 mn and 1.24 mn

visits to Waterpark and Aquarium,

respectively

The no. of user generated contents

(“UGC”) themed “Atlantis Sanya” on

the app “Tik Tok” surpassed 1.8 bn

Room revenue Other operational revenue

13

99

18

Key Data Overview

Average Price per Unit

RMB7 million

Total Units

1,004

Total Construction Area

161,082 Square

Meters

Average Price per Square Meter

RMB63,000

Strong Financial Performance of Atlantis Sanya (cont’d)

Units

construct

ed

Units

presold

Delivered

in 2018

Delivered

in 2019

can be

sold/deli

vered in

2020

Villa 197 190 - 176 21

Apartments 807 794 764 28 15

Total 1,004 984 764 204 36

Resident vacation units - Tang Residence Commentary

28 of sold apartment units and 176 of sold villas

were transferred to customers in 2019

RMB 3,433.6 mn of contract liabilities related to

property sales was recognized as revenue in 2019

Within 984 units presold, the remaining 2

apartments of and 14 villas are expected to be

transferred when the ownerships are transferred

subject to applicable laws and regulations.

235 units of apartments and 10 villas are managed

by Albion

http://www.google.com/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&ved=&url=http://www.asiavillas.com/&psig=AOvVaw1FRNPZZ9U2rQAnLjyFSI_V&ust=1536125537676147

http://www.google.com/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&ved=&url=http://www.asiavillas.com/&psig=AOvVaw1FRNPZZ9U2rQAnLjyFSI_V&ust=1536125537676147

https://www.google.com/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&ved=2ahUKEwjqlKbW0KDdAhVLfSsKHSFjDNcQjRx6BAgBEAU&url=https://www.flaticon.com/free-icon/apartments_122960&psig=AOvVaw0iiQpssm6kzpBydwdFTNdx&ust=1536125762358123

https://www.google.com/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&ved=2ahUKEwjqlKbW0KDdAhVLfSsKHSFjDNcQjRx6BAgBEAU&url=https://www.flaticon.com/free-icon/apartments_122960&psig=AOvVaw0iiQpssm6kzpBydwdFTNdx&ust=1536125762358123

100

18

Future Prospect – Lijiang FOLIDAY Town

Lijiang

Kunming

Dali

Chengdu

Chongqing

Nanning

Lijiang Foliday Town

Overview

Sightseeing attractions, Club Med resort and other accommodations (including a Club

Med resort), recreational facilities, custom resort inns and accommodations, shows, local

events and tours.

Timeline

Construction of Club Med Resort and international tourism center started in Feb 2019。Other portion commences construction in stages upon local government approval and

construction plan. The project will be completed in stages starting from either late 2020 or

early 2021 and will achieve full completion in the following 2 to 3 years.

Cost

Total cost incurred: RMB 746.2 mn as of 31 Dec 2019. Project development costs

(mainly including the cost to acquire the land use right and construction cost) is expected

to be approximately RMB 4 billion1.

(Total GFA: approx. 310,000 m2)

Lijiang FOLIDAY Town details

Note: 1 Construction delivery should comply with relevant policies and obtain relevant approvals

15

101

18

Future Prospect – Taicang FOLIDAY Town

Taicang

Nanjing

Hangzhou

Wuxi

Suzhou

Changzhou

Shanghai

Ningbo

Chongqing

Nanning

Taicang FOLIDAY Town

(Total GFA: approx. 1,286,000 m2)

Overview

One of the largest indoor snow slope in East China (designed by

CDA), a sports park, a resort, a European style town, and saleable

vacation units targeting mid-to high end customers

Timeline

Construction started in Jan 2019. The construction of the commercial

land display Centre and show units was completed and planned to

initiate presale within 2020.The project is expected to be completed in

stages starting from 2021 and will achieve full completion in the

following 3 to 4 years.

Cost

Total cost incurred: RMB 2,662.8 mn as of 31 Dec 2019. Project

development costs (mainly including the cost to acquire the land use

right and construction cost) is expected to be approximately RMB 13.2

billion1.

Taicang FOLIDAY Town details

Note: 1 Construction delivery should comply with relevant policies and obtain relevant approvals

16

102

18

Fosun Tourism Group led the recovery of post-pandemic Sanya tourism

Re-Open Performance

ANJI April 6th （Mon）

YANQING April 20th（Mon）

GUILIN April 27th （Mon）

SANYA May 1st （Fri）

GOLDEN COAST May 28th

（Thu）

Nearly sold out each weekend since May Day

Sold out on May Day and June 1st

Occupancy rate over 50% on May Day and June 1st

Weekend occupancy rate over 50% on May Day and June 1st

90% occupancy rate on June 1st

1,144 1,139

1,712

67% 66%

84%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

0

200

400

600

800

1,000

1,200

1,400

1,600

1,800

28 March Ching Ming Long

Weekend

May Day

ADR

Occ. Rate

Sanya Atlantis showed recovery on ADR and occupancy rate

103

18

700k+ Visitors、25k+ Buyers 70k+ New fans，

reaching to 282k Fans

Hot sale items with 64.42M+ GMV

Fliggy Super Brand Day major platform

Fosun 515 home page

“Fosun 515+Fliggy Super Brand Day”

bi-directional flow between two major

platforms

Taobao app exposure Fliggy app opening screen

Fliggy app home page banner

515 Campaign with 100M GMV

104

18

515 livestreaming by Wei Ya

GMV37.6M

51 live streams and 10 self-media promotion

articles with content enhancement→customer

recommend→ KOL marketing，continued

products exposure and conversion.

Total viewers of 31M，increased online followers

by 38,000, 47.5% of store traffic directed by

KOLs.

• KOL marketing

——3 TOP KOLs promoted 64M sales

• Mid-level influencer multi-category customer

marketing

—— 26 travel bloggers and anchors covering

customers in tourism/ beauty/ family/ home/

food, promoted GMV of 970,000

• 21 store live streams

—— Store live streaming strengthened resort

related content, introduced products, relieved

customer service pressure and led 350,000

GMV

516 Livestreaming by Chen He

GMV10.9M

514 Xiyou promotion article

GMV15.7M

Celebrity Live-streaming with 64M GMV

105

18

4

1. Resorts 2. Tourism

destinations

*

Fanshow: Develop and organize

entertainment performances in various

scenic spots

Miniversity: Joint venture with Mattel, a

one-stop international learning and playing

club for children Foryou Ski: Indoor Ski

Simulator

Foryou Club: Exclusive membership loyalty

program

Thomas Cook Lifestyle Service

Platform: Integrated with Foryou Travel,

Kuyi and lifestyle services platform, aim to

transit FOLIDAY distribution platform into a

lifestyle platform under Thomas Cook in

Summer 2020

Taicang FOLIDAY Town and

Lijiang FOLIDAY Town started

construction in 2019

Fosun Tourism Group Business Overview

Casa Cook &

Cook’s Club

3. Tourism related services

& solutions

Acquired light luxury hotel brands

previously owned by Thomas Cook,

plan to expand via Franchise Contracts

Note: * Managed by Kerzner, a world-renowned operator of premium properties 1 In terms of FY2019 revenue according to Frost & Sullivan report;

The world's largest provider of all-inclusive

leisure resorts focused on

family customers 1

The third Atlantis in the world,

a tourism destination with over

RMB10 billion total investment

Club Med Joyview is tailored for Chinese

market, aims to meet the growing demand

of Chinese families for leisure holidays

around cities

Operate and manage vacation

properties and tourist destinations

https://www.google.com/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&ved=2ahUKEwjrxIuzn6HdAhVYfCsKHYk8AWMQjRx6BAgBEAU&url=https://www.freeiconspng.com/images/airplane-icon-png&psig=AOvVaw3CEczVSCQssMB48UvLYY5L&ust=1536146916121404






106

18

FOLIDAY Ecosystem

Multiple “touch

points” to interact with

customers

Capture more customers and lead to higher customer

stickiness

Services and solutions in various tourism and

leisure settings

One-stop tourism

and leisure

solutions

Attract more participants

to expand offerings and

enhance customer

experiences

Resorts and

tourism

destinations

*

5

107

18

Everyday is FOLIDAY

FOLIDAY APP THOMAS COOK微信小程序

复星旅游文化集团(简称“复星旅文”或“FOLIDAY”)，是聚焦休闲度假的全球领先综合性旅游集团之一，是全球最大的休闲度假村集团(以2019年收入计, 引自于独立国际咨询公司弗若斯特沙利文行业报告)。

作为全球家庭休闲度假的引领者，复星旅文提出“Everyday is FOLIDAY”，即“快乐每一天”的理念，致力于打造FOLIDAY的全新生活方式。复星旅文于2018年在香港联交所主板上市(01992.HK)，是复星 “健康、快乐、富足”三大战略业务之一“快乐”板块的重要组成部分。

fosun internationlal limited€¦ · horizontal collaboration products combination creating...

Documents